Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
June 29, 2021 04:00 AM EDTUpdated July 2, 12:28 PM
R&D
Cell/Gene Tx
Manufacturing

Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

Kyle Blankenship

With Mod­er­na and Pfiz­er/BioN­Tech paving the road for mR­NA ther­a­peu­tics, a gold rush is un­der­way across bio­phar­ma to take that promis­ing ba­ton and run with …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Out­look's shares crash as wet AMD drug flunks Phase 3 test

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

A service from the Financial Times